Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
Authors:
- 26 November 2019
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 39 (1) , 207-216
Abstract
This work aimed to assess treatment adherence in rheumatoid arthritis patients with several tools and to identify factors associated with poor adherence.Keywords
This publication has 34 references indexed in Scilit:
- Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patientsJournal of Medical Economics, 2011
- Measurement and Rates of Persistence With and Adherence to Biologics for Rheumatoid Arthritis: A Systematic ReviewClinical Therapeutics, 2011
- Inadequate Therapy Behavior Is Associated to Disease Flares in Patients With Rheumatoid Arthritis Who Have Achieved Remission With Disease-Modifying Antirheumatic DrugsThe American Journal of the Medical Sciences, 2010
- Temporal stability of beliefs about medicines: Implications for optimising adherencePatient Education and Counseling, 2010
- Medication AdherenceCirculation, 2009
- Compliance with biologic therapies for rheumatoid arthritis: Do patient out‐of‐pocket payments matter?Arthritis Care & Research, 2008
- Medication Compliance and Persistence: Terminology and DefinitionsValue in Health, 2008
- Adherence to MedicationNew England Journal of Medicine, 2005
- Validation of a novel satisfaction questionnaire for patients with rheumatoid arthritis receiving outpatient clinical nurse specialist care, inpatient care, or day patient team careArthritis Care & Research, 2003
- Concurrent and Predictive Validity of a Self-reported Measure of Medication AdherenceMedical Care, 1986